A new trading day began on Friday, with Processa Pharmaceuticals Inc (NASDAQ: PCSA) stock price down -10.68% from the previous day of trading, before settling in for the closing price of $0.21. PCSA’s price has ranged from $0.15 to $1.50 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 22.65% over the past five years. Meanwhile, its annual earnings per share averaged 86.95%. With a float of $42.12 million, this company’s outstanding shares have now reached $50.35 million.
Let’s look at the performance matrix of the company that is accounted for 10 employees.
Processa Pharmaceuticals Inc (PCSA) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Processa Pharmaceuticals Inc is 16.34%, while institutional ownership is 5.99%. The most recent insider transaction that took place on Jan 27 ’25, was worth 9,889. In this transaction Director of this company bought 12,400 shares at a rate of $0.80, taking the stock ownership to the 12,400 shares. Before that another transaction happened on Jan 27 ’25, when Company’s Chief Executive Officer bought 87,200 for $0.80, making the entire transaction worth $69,542. This insider now owns 87,200 shares in total.
Processa Pharmaceuticals Inc (PCSA) Performance Highlights and Predictions
In its latest quarterly report, released on 9/30/2024, the company reported earnings of -1.03 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.08 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 86.95% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 59.35% during the next five years compared to 22.65% growth over the previous five years of trading.
Processa Pharmaceuticals Inc (NASDAQ: PCSA) Trading Performance Indicators
Here are Processa Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.45.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.32, a number that is poised to hit -0.10 in the next quarter and is forecasted to reach -0.26 in one year’s time.
Technical Analysis of Processa Pharmaceuticals Inc (PCSA)
Processa Pharmaceuticals Inc (NASDAQ: PCSA) saw its 5-day average volume 2.2 million, a negative change from its year-to-date volume of 8.5 million. As of the previous 9 days, the stock’s Stochastic %D was 39.33%.
During the past 100 days, Processa Pharmaceuticals Inc’s (PCSA) raw stochastic average was set at 6.14%, which indicates a significant decrease from 14.55% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0161 in the past 14 days, which was lower than the 0.0423 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.2243, while its 200-day Moving Average is $0.4883. Nevertheless, the first resistance level for the watch stands at $0.2019 in the near term. At $0.2149, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.2253. If the price goes on to break the first support level at $0.1785, it is likely to go to the next support level at $0.1681. Assuming the price breaks the second support level, the third support level stands at $0.1551.
Processa Pharmaceuticals Inc (NASDAQ: PCSA) Key Stats
With a market capitalization of 9.52 million, the company has a total of 50,349K Shares Outstanding. Currently, annual sales are 0 K while annual income is -11,850 K. The company’s previous quarter sales were 0 K while its latest quarter income was -3,930 K.
